Back to Search Start Over

62-LB: Quantifying Insulin-Mediated and Noninsulin Mediated Glucose Disposal during Exercise in Patients with Type 1 Diabetes.

Authors :
NGUYEN, THANH-TIN P.
JACOBS, PETER G.
CASTLE, JESSICA R.
WILSON, LEAH M.
BRANIGAN, DEBORAH
GABO, VIRGINIA
SENF, BRIAN
GUILLOT, FLORIAN H.
YOUSSEF, JOSEPH EL
Source :
Diabetes. 2019 Supplement, Vol. 68, pN.PAG-N.PAG. 1p.
Publication Year :
2019

Abstract

Introduction: Glycemic control during exercise is challenging for people with type 1 diabetes. Better quantification of insulin dynamics at different exercise intensities and across insulin loading conditions is necessary for accurate insulin dosing during exercise. Methods: Twenty seven participants with type 1 diabetes were evaluated during 3 separate 10-hour fasting aerobic exercise studies with low, medium, and high levels of insulin infusion (100%, 150%, and 300% of basal rate) across two exercise arms: moderate (40-45% of VO2 max), and intense (60-65% of VO2 max) exercise. Glucose levels were clamped during a 3-hour run-in period, followed by 45 minutes of exercise on a treadmill. 6,6-2H2-dideuterated glucose was infused to match endogenous glucose production during the entire trial. Glucose tracer data were fitted to a two-compartment ODE model, solved via Bayesian inference. We intend to quantify insulin and non-insulin mediated disposal of glucose by observing the rate of disposal (Rd) across different rates of insulin infusion in each exercise arm. Results: Area under the curve (AUC) of Rd during 45 minutes of moderate exercise increased by 0.084 mmol/L for every percent increase in baseline insulin infusion rate (95% CI=0.064-0.104, p<0.001). AUC during intense exercise increased by 0.109 mmol/L (95% CI= 0.079-0.139, p<0.001). Mixed-effects model analysis showed no difference between exercise arms. Conclusion: Results indicate Rd is substantial during exercise but that the difference in glucose uptake during aerobic exercise at 40-45% VO2 max may be comparable with 60-65% VO2 max. Disclosure: T.P. Nguyen: None. P.G. Jacobs: Stock/Shareholder; Self; Pacific Diabetes Technologies. J.R. Castle: Advisory Panel; Self; Novo Nordisk Inc., Zealand Pharma A/S. Consultant; Self; Dexcom, Inc. Research Support; Self; Dexcom, Inc., Xeris Pharmaceuticals, Inc. L.M. Wilson: None. D. Branigan: None. V. Gabo: None. B. Senf: None. F.H. Guillot: None. J. El Youssef: None. Funding: National Institutes of Health [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00121797
Volume :
68
Database :
Academic Search Index
Journal :
Diabetes
Publication Type :
Academic Journal
Accession number :
152326393
Full Text :
https://doi.org/10.2337/db19-62-LB